A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Active, not recruiting · NCT07300085 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) | Infections, RNA Virus Infections, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Active, not recruiting | Phase 1 | 2026-08-19 | NCT07300085 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| California Clinical Trials Medical Group (CCTMG) managed by Parexel | Glendale | United States | 1 |
| Parexel ( Site 0001) | Glendale | United States | 1 |
| Parexel ( Site 0002) | Baltimore | United States | 1 |
| Parexel International - EPCU Baltimore | Baltimore | United States | 1 |